Treatment of Angelman Syndrome Using ASO targeting UBE3A-AS
$461,612
2017
M1801221: 2017-2018
Treatment of Angelman Syndrome Using ASO targeting UBE3A-AS
This program supported further exploration of various ASO candidates for paternal gene activation through antisense technology.
Principle Investigator
Scott Dindot, PhD